First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis
Open Access
- 7 August 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0134703
Abstract
The current trial was a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the recombinant monoclonal anti−interleukin-20 (IL-20) antibody, NNC0109-0012, which targets the inflammatory cytokine IL-20. In total, 48 patients aged 18 to 75 years with moderate to severe stable chronic plaque psoriasis with affected body surface area ≥15% and physician global assessment score ≥3 were enrolled in this randomized, double-blind, multicenter, placebo-controlled, phase 1 dose-escalation trial. Patients were randomized within each single dose cohort (0.01, 0.05, 0.2, 0.6, 1.5, or 3.0 mg/kg) or multiple dose cohort (0.05, 0.2, 0.5, 1.0, or 2.0 mg/kg; 1 dose every other week for 7 weeks) of NNC0109-0012 or placebo in a 3:1 ratio. In the expansion phase, 7 patients were randomized to weekly doses of 2.0 mg/kg NNC0109-0012 or placebo for 7 weeks. The primary objective, safety and tolerability, was assessed by evaluating adverse events (AEs). Additional endpoints included pharmacokinetics, pharmacodynamics, and clinical response (assessed using the Psoriasis Area and Severity Index [PASI] score). AEs were reported in 85% of patients (n = 40) in the initial study phases (NNC0109-0012, 83%; placebo, 92%) and in 4 of 7 patients in the multiple-dose expansion phase. One serious AE was reported but was judged not to be causally related to NNC0109-0012. No dose-limiting toxicities were reported. NNC0109-0012 pharmacokinetics was similar to other monoclonal antibodies, with an average half-life of approximately 3 weeks. There was a dose-proportional increase in area under the curve and maximum concentration after single dosing. No substantial changes in pharmacodynamic parameters were observed. The expansion phase was terminated early due to apparent lack of PASI improvement. Single and multiple doses of NNC0109-0012, ranging from 0.05 to 3.0 mg/kg, were well tolerated in patients with psoriasis and exhibited pharmacokinetics similar to that of other monoclonal antibodies. ClinicalTrials.gov NCT01261767Keywords
This publication has 29 references indexed in Scilit:
- Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasisBritish Journal of Dermatology, 2012
- Trends in incidence of adult-onset psoriasis over three decades: A population-based studyJournal of the American Academy of Dermatology, 2009
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004Journal of the American Academy of Dermatology, 2009
- Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in WomenArchives of internal medicine (1960), 2007
- Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002Current Medical Research and Opinion, 2006
- Psoriasis: emerging therapeutic strategiesNature Reviews Drug Discovery, 2005
- The prevalence of psoriasis in African Americans: Results from a population-based studyJournal of the American Academy of Dermatology, 2005
- Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment DissatisfactionJournal of Investigative Dermatology Symposium Proceedings, 2004
- PsoriasisThe Lancet, 2003
- Novel immunotherapies for psoriasisTrends in Immunology, 2002